Robert E Maclaren

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3878205/robert-e-maclaren-publications-by-year.pdf
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284 papers	7,472 citations	46 h-index	77 g-index
290 ext. papers	9,107 ext. citations	6 avg, IF	6.31 L-index

#	Paper	IF	Citations
284	Gene therapy and treatment trials **2022**, 63-66		
283	Bioengineering strategies for restoring vision.. *Nature Biomedical Engineering*, **2022**,	19	4
282	Retinal cadherins and the retinal cadherinopathies: Current concepts and future directions.. *Progress in Retinal and Eye Research*, **2022**, 101038	20.5	1
281	The effect of cataract on colour vision measurement with the Low Vision Cambridge Colour Test: Providing an adjustment factor for clinical trials. *Ophthalmology Science*, **2022**, 100153		0
280	Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids.. *Translational Vision Science and Technology*, **2022**, 11, 3	3.3	0
279	Choroideremia and Other Hereditary Conditions Manifesting with Choroidal Atrophy **2022**, 3997-4012		
278	Characterizing Visual Fields in RPGR Related Retinitis Pigmentosa Using Octopus Static-Automated Perimetry.. *Translational Vision Science and Technology*, **2022**, 11, 15	3.3	
277	RPGR-Related X-Linked Retinitis Pigmentosa Carriers with a Severe "Male Pattern". *Ophthalmologica*, **2021**, 244, 60-67	3.7	6
276	Early Cone Photoreceptor Outer Segment Length Shortening in RPGR X-Linked Retinitis Pigmentosa. *Ophthalmologica*, **2021**, 244, 281-290	3.7	6
275	The Scope of Pathogenic ABCA4 Mutations Targetable by CRISPR DNA Base Editing Systems-A Systematic Review.. *Frontiers in Genetics*, **2021**, 12, 814131	4.5	0
274	An analysis of the Kozak consensus in retinal genes and its relevance to gene therapy. *Molecular Vision*, **2021**, 27, 233-242	2.3	
273	In Silico Analysis of Pathogenic Single Nucleotide Variants and Their Amenability to Base Editing as a Potential Lead for Therapeutic Intervention.. *Genes*, **2021**, 12,	4.2	1
272	First-In-Human Robot-Assisted Subretinal Drug Delivery Under Local Anaesthesia A Randomised Clinical Trial. *American Journal of Ophthalmology*, **2021**,	4.9	4
271	Structural and Functional Characteristics of Color Vision Changes in Choroideremia. *Frontiers in Neuroscience*, **2021**, 15, 729807	5.1	0
270	CRISPR Systems Suitable for Single AAV Vector Delivery. *Current Gene Therapy*, **2021**,	4.3	1
269	CDHR1-related late-onset macular dystrophy: further insights. *Eye*, **2021**, 35, 2901-2902	4.4	3
268	North Carolina macular dystrophy shows a particular drusen phenotype and atrophy progression. *British Journal of Ophthalmology*, **2021**,	5.5	3

267	Genome-Editing Strategies for Treating Human Retinal Degenerations. *Human Gene Therapy*, **2021**, 32, 247-259	4.8	8
266	Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells. *Gene Therapy*, **2021**, 28, 265-276	4	8
265	Analysis of Pathogenic Variants Correctable With CRISPR Base Editing Among Patients With Recessive Inherited Retinal Degeneration. *JAMA Ophthalmology*, **2021**, 139, 319-328	3.9	12
264	Accurate Quantification of AAV Vector Genomes by Quantitative PCR. *Genes*, **2021**, 12,	4.2	1
263	Microperimetry Hill of Vision and Volumetric Measures of Retinal Sensitivity. *Translational Vision Science and Technology*, **2021**, 10, 12	3.3	4
262	Prevalence and phenotype associations of complement factor I mutations in geographic atrophy. *Human Mutation*, **2021**, 42, 1139-1152	4.7	3
261	ON-bipolar cell gene expression during retinal degeneration: Implications for optogenetic visual restoration. *Experimental Eye Research*, **2021**, 207, 108553	3.7	5
260	Chimeric human opsins as optogenetic light sensitisers. *Journal of Experimental Biology*, **2021**, 224,	3	1
259	A 2020 vision of ocular gene therapy. *Gene Therapy*, **2021**, 28, 217-219	4	
258	Reduced vessel density in deep capillary plexus correlates with retinal layer thickness in choroideremia. *British Journal of Ophthalmology*, **2021**, 105, 687-693	5.5	5
257	"Genetic and clinical findings in an ethnically diverse retinitis pigmentosa cohort associated with pathogenic variants in EYS". *Eye*, **2021**, 35, 1440-1449	4.4	1
256	A low-cost telescope for enhanced stimulus visual field coverage in functional MRI. *Journal of Neuroscience Methods*, **2021**, 350, 109023	3	1
255	Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2021**, 259, 905-910	2.8	2
254	Low-contrast visual acuity versus low-luminance visual acuity in choroideremia. *Australasian journal of optometry, The*, **2021**, 104, 90-94	2.7	3
253	Choroideremia and Other Hereditary Conditions Manifesting with Choroidal Atrophy **2021**, 1-16		
252	Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?. *Expert Opinion on Orphan Drugs*, **2021**, 9, 13-24	1.1	1
251	CRISPR genome engineering for retinal diseases. *Progress in Molecular Biology and Translational Science*, **2021**, 182, 29-79	4	5
250	Low luminance visual acuity as a clinical measure and clinical trial outcome measure: a scoping review. *Ophthalmic and Physiological Optics*, **2021**, 41, 213-223	4.1	4

249	AAV Induced Expression of Human Rod and Cone Opsin in Bipolar Cells of a Mouse Model of Retinal Degeneration.. *BioMed Research International*, **2021**, 2021, 1-8	3	15
248	Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. *Acta Ophthalmologica*, **2021**, 99, 805-811	3.7	1
247	Reply to Comment on: Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy. *American Journal of Ophthalmology*, **2021**, 222, 397-398	4.9	
246	Low Luminance Visual Acuity and Low Luminance Deficit in Choroideremia and RPGR-Associated Retinitis Pigmentosa. *Translational Vision Science and Technology*, **2021**, 10, 28	3.3	1
245	Chronic untreated retinal detachment in a patient with choroideremia provides insight into the disease process and potential therapy. *European Journal of Ophthalmology*, **2021**, 1120672121994722	1.9	
244	Clinical applications of microperimetry in RPGR-related retinitis pigmentosa: a review. *Acta Ophthalmologica*, **2021**, 99, 819-825	3.7	0
243	Deep phenotyping of the Cdhr1 mouse validates its use in pre-clinical studies for human CDHR1-associated retinal degeneration. *Experimental Eye Research*, **2021**, 208, 108603	3.7	3
242	Expression of Rab Prenylation Pathway Genes and Relation to Disease Progression in Choroideremia. *Translational Vision Science and Technology*, **2021**, 10, 12	3.3	0
241	Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa. *Nature Communications*, **2021**, 12, 4934	17.4	6
240	Therapy Approaches for Stargardt Disease. *Biomolecules*, **2021**, 11,	5.9	4
239	Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina. *Molecular Therapy - Methods and Clinical Development*, **2021**, 22, 52-65	6.4	3
238	RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4. *Retina*, **2021**, 41, 2122-2131	3.6	0
237	Endpoints for Measuring Efficacy in Clinical Trials for Inherited Retinal Disease. *International Ophthalmology Clinics*, **2021**, 61, 63-78	1.7	
236	Effect of AAV-Mediated Rhodopsin Gene Augmentation on Retinal Degeneration Caused by the Dominant P23H Rhodopsin Mutation in a Knock-In Murine Model. *Human Gene Therapy*, **2020**, 31, 730-742	4.8	8
235	Highest reported visual acuity after electronic retinal implantation. *Acta Ophthalmologica*, **2020**, 98, 736-740	3.7	8
234	Next generation sequencing using phenotype-based panels for genetic testing in inherited retinal diseases. *Ophthalmic Genetics*, **2020**, 41, 331-337	1.2	9
233	RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain. *Angiogenesis*, **2020**, 23, 493-513	10.6	16
232	A Semiautomated, Phenotypic, Scratch Assay for Assessing Retinal Pigment Epithelial Cell Wound Healing. *Journal of Ocular Pharmacology and Therapeutics*, **2020**, 36, 257-266	2.6	

231	Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. *Nature Medicine*, **2020**, 26, 354-359	50.5	105
230	An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK. *Advances in Therapy*, **2020**, 37, 1233-1247	4.1	11
229	Repair of Retinal Degeneration following Ex Vivo Minicircle DNA Gene Therapy and Transplantation of Corrected Photoreceptor Progenitors. *Molecular Therapy*, **2020**, 28, 830-844	11.7	11
228	Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants. *Cell Reports*, **2020**, 30, 881-892.e5	10.6	8
227	Validation of electronic visual acuity (EVA) measurement against standardised ETDRS charts in patients with visual field loss from inherited retinal degenerations. *British Journal of Ophthalmology*, **2020**, 104, 924-931	5.5	4
226	RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	33
225	Reply to Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. *American Journal of Ophthalmology*, **2020**, 212, 187-188	4.9	6
224	Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations. *JAMA Ophthalmology*, **2020**, 138, 544-551	3.9	9
223	Monitoring progression of retinitis pigmentosa: current recommendations and recent advances. *Expert Opinion on Orphan Drugs*, **2020**, 8, 67-78	1.1	16
222	Correcting visual loss by genetics and prosthetics. *Current Opinion in Physiology*, **2020**, 16, 1-7	2.6	1
221	Crossover to Photodynamic Therapy or Micropulse Laser After Failure of Primary Treatment of Chronic Central Serous Chorioretinopathy: The REPLACE Trial. *American Journal of Ophthalmology*, **2020**, 216, 80-89	4.9	8
220	Peripapillary Sparing in Autosomal Recessive Bestrophinopathy. *Ophthalmology Retina*, **2020**, 4, 523-529	3.8	3
219	Comment on: Sector retinitis pigmentosa caused by mutations of the RHO gene. *Eye*, **2020**, 34, 1477-1478	4.4	1
218	Inclusion of PF68 Surfactant Improves Stability of rAAV Titer when Passed through a Surgical Device Used in Retinal Gene Therapy. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 99-106	6.4	3
217	Association of Messenger RNA Level With Phenotype in Patients With Choroideremia: Potential Implications for Gene Therapy Dose. *JAMA Ophthalmology*, **2020**, 138, 128-135	3.9	7
216	A distinct retinal pigment epithelial cell autofluorescence pattern in choroideremia predicts early involvement of overlying photoreceptors. *Acta Ophthalmologica*, **2020**, 98, e322-e327	3.7	3
215	HYPERREFLECTIVE FOCI AS A PATHOGENETIC BIOMARKER IN CHOROIDEREMIA. *Retina*, **2020**, 40, 1634-1640	3.6	8
214	Dynamic in vivo quantification of rod photoreceptor degeneration using fluorescent reporter mouse models of retinitis pigmentosa. *Experimental Eye Research*, **2020**, 190, 107895	3.7	3

213	Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa: A Multicenter Safety Study of the OkuStim® System (TESOLA-Study). *Ophthalmic Research*, **2020**, 63, 234-243	2.9	9
212	The Impact of Progressive Visual Field Constriction on Reading Ability in an Inherited Retinal Degeneration. *Ophthalmologica*, **2020**, 243, 207-216	3.7	1
211	Association of a Novel Intronic Variant in RPGR With Hypomorphic Phenotype of X-Linked Retinitis Pigmentosa. *JAMA Ophthalmology*, **2020**, 138, 1151-1158	3.9	3
210	Assessment of AAV Dual Vector Safety in the Mouse Model of Stargardt Disease. *Translational Vision Science and Technology*, **2020**, 9, 20	3.3	5
209	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	11
208	Optogenetic Gene Therapy for the Degenerate Retina: Recent Advances. *Frontiers in Neuroscience*, **2020**, 14, 570909	5.1	16
207	Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. *Expert Opinion on Investigational Drugs*, **2020**, 29, 1163-1170	5.9	24
206	Binocular Visual Function in a Pre-Presbyopic Patient with Uniocular Cataract Undergoing Cataract Surgery with a Multifocal Intraocular Lens. *Clinical Ophthalmology*, **2020**, 14, 2001-2009	2.5	1
205	Inner retinal thickening affects microperimetry thresholds in the presence of photoreceptor thinning in patients with retinitis pigmentosa. *British Journal of Ophthalmology*, **2020**,	5.5	5
204	CRISPR-Cas9 DNA Base-Editing and Prime-Editing. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	66
203	Analysis of Early Cone Dysfunction in an In Vivo Model of Rod-Cone Dystrophy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
202	Promoter Orientation within an AAV-CRISPR Vector Affects Cas9 Expression and Gene Editing Efficiency. *CRISPR Journal*, **2020**, 3, 276-283	2.5	0
201	Genetic and Clinical Findings in an Ethnically Diverse Cohort with Retinitis Pigmentosa Associated with Pathogenic Variants in CERKL. *Genes*, **2020**, 11,	4.2	2
200	CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. *Retina*, **2020**, 40, 160-168	3.6	30
199	RPGR gene therapy presents challenges in cloning the coding sequence. *Expert Opinion on Biological Therapy*, **2020**, 20, 63-71	5.4	6
198	Retinal stem cell transplantation: Balancing safety and potential. *Progress in Retinal and Eye Research*, **2020**, 75, 100779	20.5	68
197	Test-retest repeatability of microperimetry in patients with retinitis pigmentosa caused by mutations in RPGR. *Clinical and Experimental Ophthalmology*, **2020**, 48, 714-715	2.4	8
196	The nanophthalmos protein TMEM98 inhibits MYRF self-cleavage and is required for eye size specification. *PLoS Genetics*, **2020**, 16, e1008583	6	11

195	CRISPR Interference-Potential Application in Retinal Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
194	The nanophthalmos protein TMEM98 inhibits MYRF self-cleavage and is required for eye size specification **2020**, 16, e1008583		
193	The nanophthalmos protein TMEM98 inhibits MYRF self-cleavage and is required for eye size specification **2020**, 16, e1008583		
192	The nanophthalmos protein TMEM98 inhibits MYRF self-cleavage and is required for eye size specification **2020**, 16, e1008583		
191	The nanophthalmos protein TMEM98 inhibits MYRF self-cleavage and is required for eye size specification **2020**, 16, e1008583		
190	Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial. *JAMA Ophthalmology*, **2019**, 137, 1247-1254	3.9	38
189	Molecular Strategies for RPGR Gene Therapy. *Genes*, **2019**, 10,	4.2	21
188	Clinical Characterization of Retinitis Pigmentosa Associated With Variants in SNRNP200. *JAMA Ophthalmology*, **2019**, 137, 1295-1300	3.9	6
187	Reply. *Ophthalmology*, **2019**, 126, e30-e31	7.3	
186	Molecular Therapies for Choroideremia. *Genes*, **2019**, 10,	4.2	7
185	Electrophysiological verification of enhanced S-cone syndrome caused by a novel c.755T>C NR2E3 missense variant. *Ophthalmic Genetics*, **2019**, 40, 29-33	1.2	3
184	Atypical choroideremia presenting with early-onset macular atrophy. *Acta Ophthalmologica*, **2019**, 97, 633-636	3.7	2
183	Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2019**, 257, 1419-1425	3.8	12
182	Clinical and Molecular Characterization of PROM1-Related Retinal Degeneration. *JAMA Network Open*, **2019**, 2, e195752	10.4	21
181	Novel non-sense mutation in RP2 (c.843_844insT/p.Arg282fs) is associated with a severe phenotype of retinitis pigmentosa without evidence of primary retinal pigment epithelium involvement. *BMJ Case Reports*, **2019**, 12,	0.9	0
180	Re: Song et al., Toxicology and Pharmacology of an AAV Vector Expressing Codon-Optimized RPGR in RPGR-Deficient Rd9 Mice. Hum Gene Ther Clin Dev 2018; 29(4):188-197. *Human Gene Therapy Clinical Development*, **2019**, 30, 40	3.2	
179	Changes in microchip position after implantation of a subretinal vision prosthesis in humans. *Acta Ophthalmologica*, **2019**, 97, e871-e876	3.7	4
178	A Quantitative Chloride Channel Conductance Assay for Efficacy Testing of AAV.BEST1. *Human Gene Therapy Methods*, **2019**, 30, 44-52	4.9	2

177	Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. *American Journal of Ophthalmology*, **2019**, 205, 1-10	4.9	24
176	The Location of Exon 4 Mutations in RP1 Raises Challenges for Genetic Counseling and Gene Therapy. *American Journal of Ophthalmology*, **2019**, 202, 23-29	4.9	12
175	AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies Inhibits Murine Choroidal Neovascularization. *Molecular Therapy - Methods and Clinical Development*, **2019**, 13, 86-98	6.4	5
174	A Specific Macula-Predominant Retinal Phenotype Is Associated With the CDHR1 Variant c.783G>A, a Silent Mutation Leading to In-Frame Exon Skipping **2019**, 60, 3388-3397		10
173	Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model. *Eye*, **2019**, 33, 1215-1223	4.4	7
172	Filtration of Short-Wavelength Light Provides Therapeutic Benefit in Retinitis Pigmentosa Caused by a Common Rhodopsin Mutation **2019**, 60, 2733-2742		9
171	Enhancement of Adeno-Associated Virus-Mediated Gene Therapy Using Hydroxychloroquine in Murine and Human Tissues. *Molecular Therapy - Methods and Clinical Development*, **2019**, 14, 77-89	6.4	14
170	Presence of corneal crystals confirms an unusual presentation of Bietti retinal dystrophy. *Ophthalmic Genetics*, **2019**, 40, 461-465	1.2	4
169	Digital Technology in Somatic and Gene Therapy Trials of Pediatric Patients With Ocular Diseases: Protocol for a Scoping Review. *JMIR Research Protocols*, **2019**, 8, e10705	2	
168	Progress in the development of novel therapies for choroideremia. *Expert Review of Ophthalmology* , **2019**, 14, 277-285	1.5	5
167	Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice. *Frontiers in Pharmacology*, **2019**, 10, 1076	5.6	17
166	A novel splice-site variant in in a patient with Usher syndrome type 1. *Ophthalmic Genetics*, **2019**, 40, 545-548	1.2	3
165	Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration. *Retina*, **2019**, 39 Suppl 1, S2-S8	3.6	25
164	A Randomized Crossover Study to Assess the Usability of Two New Vision Tests in Patients with Low Vision. *Optometry and Vision Science*, **2019**, 96, 443-452	2.1	2
163	A detailed in vivo analysis of the retinal nerve fibre layer in choroideremia. *Acta Ophthalmologica*, **2019**, 97, e589-e600	3.7	4
162	Unilateral pigmentary retinopathy: a retrospective case series. *Acta Ophthalmologica*, **2019**, 97, e601-e617	3.7	11
161	Reply. *Ophthalmology*, **2019**, 126, e11	7.3	
160	An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Mice. *Human Gene Therapy*, **2019**, 30, 590-600	4.8	52

159	Near-Infrared Autofluorescence in Choroideremia: Anatomic and Functional Correlations. *American Journal of Ophthalmology*, **2019**, 199, 19-27	4.9	17
158	Macular spatial distribution of preserved autofluorescence in patients with choroideremia. *British Journal of Ophthalmology*, **2019**, 103, 933-937	5.5	11
157	Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results. *American Journal of Ophthalmology*, **2019**, 197, 65-73	4.9	82
156	Optimisation of dark adaptation time required for mesopic microperimetry. *British Journal of Ophthalmology*, **2019**, 103, 1092-1098	5.5	10
155	Two Novel CAPN5 Variants Associated with Mild and Severe Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy Phenotypes. *Ocular Immunology and Inflammation*, **2019**, 27, 693-698	2.8	12
154	VASCULAR ALTERATIONS REVEALED WITH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN PATIENTS WITH CHOROIDEREMIA. *Retina*, **2019**, 39, 1200-1205	3.6	18
153	Emerging In Vitro 3D Tumour Models in Nanoparticle-Based Gene and Drug Therapy. *Trends in Biotechnology*, **2018**, 36, 477-480	15.1	1
152	Gene therapy for the treatment of X-linked retinitis pigmentosa. *Expert Opinion on Orphan Drugs*, **2018**, 6, 167-177	1.1	23
151	A clinical-grade gene therapy vector for pharmacoresistant epilepsy successfully overexpresses NPY in a human neuronal cell line. *Seizure: the Journal of the British Epilepsy Association*, **2018**, 55, 25-29	3.2	6
150	The Biological Activity of AAV Vectors for Choroideremia Gene Therapy Can Be Measured by Prenylation of RAB6A. *Molecular Therapy - Methods and Clinical Development*, **2018**, 9, 288-295	6.4	14
149	Retinal Degeneration in Choroideremia follows an Exponential Decay Function. *Ophthalmology*, **2018**, 125, 1122-1124	7.3	23
148	Implantation, removal and replacement of subretinal electronic implants for restoration of vision in patients with retinitis pigmentosa. *Current Opinion in Ophthalmology*, **2018**, 29, 239-247	5.1	15
147	Assessment of the Electronic Retinal Implant Alpha AMS in Restoring Vision to Blind Patients with End-Stage Retinitis Pigmentosa. *Ophthalmology*, **2018**, 125, 432-443	7.3	80
146	Differential roles for cryptochromes in the mammalian retinal clock. *FASEB Journal*, **2018**, 32, 4302-4314	0.9	14
145	Stem Cell Treatment for Age-Related Macular Degeneration: the Challenges **2018**, 59, AMD78-AMD82		16
144	Real-world refractive outcomes of toric intraocular lens implantation in a United Kingdom National Health Service setting. *BMC Ophthalmology*, **2018**, 18, 30	2.3	8
143	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. *American Journal of Human Genetics*, **2018**, 103, 3-18	11	27
142	Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. *Ophthalmology*, **2018**, 125, 1547-1555	7.3	111

141	Ocular gene therapy for choroideremia: clinical trials and future perspectives. *Expert Review of Ophthalmology*, **2018**, 13, 129-138	1.5	10
140	Human Retinal Explant Culture for Ex Vivo Validation of AAV Gene Therapy. *Methods in Molecular Biology*, **2018**, 1715, 289-303	1.4	13
139	Vector Shedding and Immunogenicity Sampling for Retinal Gene Therapy. *Methods in Molecular Biology*, **2018**, 1715, 359-371	1.4	5
138	Retinal Gene Therapy for Choroideremia: In Vitro Testing for Gene Augmentation Using an Adeno-Associated Viral (AAV) Vector. *Methods in Molecular Biology*, **2018**, 1715, 89-97	1.4	1
137	A splice-site variant in FLVCR1 produces retinitis pigmentosa without posterior column ataxia. *Ophthalmic Genetics*, **2018**, 39, 263-267	1.2	16
136	Exploring the Variable Phenotypes of RPGR Carrier Females in Assessing their Potential for Retinal Gene Therapy. *Genes*, **2018**, 9,	4.2	21
135	A Novel Achromatopsia Mouse Model Resulting From a Naturally Occurring Missense Change in Cngb3 **2018**, 59, 6102-6110		3
134	Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. *Nature Medicine*, **2018**, 24, 1507-1512	50.5	108
133	Olfactory Dysfunction in Patients With CNGB1-Associated Retinitis Pigmentosa. *JAMA Ophthalmology*, **2018**, 136, 761-769	3.9	7
132	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153	11	18
131	Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience. *American Journal of Ophthalmology*, **2018**, 193, 130-142	4.9	91
130	Choroideremia: molecular mechanisms and development of AAV gene therapy. *Expert Opinion on Biological Therapy*, **2018**, 18, 807-820	5.4	22
129	Effects of pupil dilation on MAIA microperimetry. *Clinical and Experimental Ophthalmology*, **2017**, 45, 489-495	2.4	13
128	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. *American Journal of Human Genetics*, **2017**, 100, 334-342	11	14
127	Structural and Functional Recovery Following Limited Iatrogenic Macular Detachment for Retinal Gene Therapy. *JAMA Ophthalmology*, **2017**, 135, 234-241	3.9	26
126	Will Nanotechnology Bring New Hope for Gene Delivery?. *Trends in Biotechnology*, **2017**, 35, 434-451	15.1	80
125	Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved Retinal Pigment Epithelium Area in Eyes With Choroideremia. *American Journal of Ophthalmology*, **2017**, 179, 110-117	4.9	43
124	A novel mutation in the dominantly inherited TOPORS gene supports haploinsufficiency as the mechanism of retinitis pigmentosa. *Ophthalmic Genetics*, **2017**, 38, 562-566	1.2	2

123	Codon-Optimized RPGR Improves Stability and Efficacy of AAV8 Gene Therapy in Two Mouse Models of X-Linked Retinitis Pigmentosa. *Molecular Therapy*, **2017**, 25, 1854-1865	11.7	69
122	Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration. *JAMA Ophthalmology*, **2017**, 135, 749-760	3.9	42
121	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *American Journal of Human Genetics*, **2017**, 100, 75-90	11	235
120	Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina. *Molecular Therapy - Nucleic Acids*, **2017**, 6, 198-208	10.7	30
119	Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 11211-11216	11.5	37
118	A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies. *Journal of Tissue Engineering*, **2017**, 8, 2041731417724413	7.5	11
117	High Symmetry of Visual Acuity and Visual Fields in RPGR-Linked Retinitis Pigmentosa **2017**, 58, 4457-4466		11
116	Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging **2017**, 58, 5575-5583		59
115	Impact of Vital Dyes on Cell Viability and Transduction Efficiency of AAV Vectors Used in Retinal Gene Therapy Surgery: An In Vitro and In Vivo Analysis. *Translational Vision Science and Technology*, **2017**, 6, 4	3.3	7
114	Limitations in Clinical Translation of Nanoparticle-Based Gene Therapy. *Trends in Biotechnology*, **2017**, 35, 1124-1125	15.1	8
113	Using Rho Kinase Inhibitors for Retinal Detachment-Reply. *JAMA Ophthalmology*, **2017**, 135, 895-896	3.9	
112	Transcorneal electrical stimulation for the treatment of retinitis pigmentosa: results from the TESOLAUK trial. *BMJ Open Ophthalmology*, **2017**, 2, e000096	3.2	16
111	Outcome of Full-Thickness Macular Hole Surgery in Choroideremia. *Genes*, **2017**, 8,	4.2	4
110	Optical Coherence Tomography in Patients With the Subretinal Implant Retina Implant Alpha IMS. *Ophthalmic Surgery Lasers and Imaging Retina*, **2017**, 48, 993-999	1.4	2
109	Interim Results of a Multicenter Trial with the New Electronic Subretinal Implant Alpha AMS in 15 Patients Blind from Inherited Retinal Degenerations. *Frontiers in Neuroscience*, **2017**, 11, 445	5.1	92
108	Gene Therapy for Color Blindness. *Yale Journal of Biology and Medicine*, **2017**, 90, 543-551	2.4	14
107	Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes. *Yale Journal of Biology and Medicine*, **2017**, 90, 611-623	2.4	41
106	The Application of CRISPR/Cas9 for the Treatment of Retinal Diseases. *Yale Journal of Biology and Medicine*, **2017**, 90, 533-541	2.4	13

105	Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan. *Yale Journal of Biology and Medicine*, **2017**, 90, 683-693	2.4	16
104	Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. *Clinical Ophthalmology*, **2017**, 11, 39-46	2.5	66
103	Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier. *Ophthalmology*, **2016**, 123, S98-S106	7.3	40
102	Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice. *Scientific Reports*, **2016**, 6, 29784	4.9	98
101	A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia **2016**, 57, 4498-4503		51
100	A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts. *Journal of Genetic Syndromes & Gene Therapy*, **2016**, 7,		6
99	The Spectrum of CHM Gene Mutations in Choroideremia and Their Relationship to Clinical Phenotype **2016**, 57, 6033-6039		61
98	Selective Automated Perimetry Under Photopic, Mesopic, and Scotopic Conditions: Detection Mechanisms and Testing Strategies. *Translational Vision Science and Technology*, **2016**, 5, 10	3.3	19
97	A Novel Method for Quantitative Serial Autofluorescence Analysis in Retinitis Pigmentosa Using Image Characteristics. *Translational Vision Science and Technology*, **2016**, 5, 10	3.3	6
96	Correlation of Optical Coherence Tomography and Autofluorescence in the Outer Retina and Choroid of Patients With Choroideremia **2016**, 57, 3674-84		55
95	Benefits of gene therapy for both eyes. *Lancet, The*, **2016**, 388, 635-6	40	4
94	Transplanted photoreceptor precursors transfer proteins to host photoreceptors by a mechanism of cytoplasmic fusion. *Nature Communications*, **2016**, 7, 13537	17.4	122
93	Hypotrichosis and juvenile macular dystrophy caused by CDH3 mutation: A candidate disease for retinal gene therapy. *Scientific Reports*, **2016**, 6, 23674	4.9	9
92	Novel gene function revealed by mouse mutagenesis screens for models of age-related disease. *Nature Communications*, **2016**, 7, 12444	17.4	56
91	Absence of Neuroplastin-65 Affects Synaptogenesis in Mouse Inner Hair Cells and Causes Profound Hearing Loss. *Journal of Neuroscience*, **2016**, 36, 222-34	6.6	20
90	Visual Acuity after Retinal Gene Therapy for Choroideremia. *New England Journal of Medicine*, **2016**, 374, 1996-8	59.2	151
89	Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4 mouse and bipolar cells in the rd1 mouse and human retina ex vivo. *Gene Therapy*, **2016**, 23, 767-774	4	19
88	Evaluation of an Optimized Injection System for Retinal Gene Therapy in Human Patients. *Human Gene Therapy Methods*, **2016**, 27, 150-8	4.9	31

87	Gene Therapy for Retinal Disease **2015**, 173-189		
86	Correlation of retinal structure and function in choroideremia carriers. *Ophthalmology*, **2015**, 122, 1274-6	7.3	35
85	Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 8415-20	11.5	80
84	Subretinal Visual Implant Alpha IMS--Clinical trial interim report. *Vision Research*, **2015**, 111, 149-60	2.1	250
83	Gene therapy for age-related macular degeneration. *Lancet, The*, **2015**, 386, 2369-70	40	3
82	Gene Therapy for Retinal Disease: What Lies Ahead. *Ophthalmologica*, **2015**, 234, 1-5	3.7	7
81	Pathogenic mechanisms and the prospect of gene therapy for choroideremia. *Expert Opinion on Orphan Drugs*, **2015**, 3, 787-798	1.1	26
80	Functional Defects in Color Vision in Patients With Choroideremia. *American Journal of Ophthalmology*, **2015**, 160, 822-31.e3	4.9	16
79	Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables. *British Journal of Ophthalmology*, **2015**, 99, 41-8	5.5	16
78	Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial. *Trials*, **2015**, 16, 419	2.8	36
77	BAX and BCL-2 polymorphisms, as predictors of proliferative vitreoretinopathy development in patients suffering retinal detachment: the Retina 4 project. *Acta Ophthalmologica*, **2015**, 93, e541-9	3.7	12
76	Recent advances and future prospects in choroideremia. *Clinical Ophthalmology*, **2015**, 9, 2195-200	2.5	33
75	Monoallelic ABCA4 Mutations Appear Insufficient to Cause Retinopathy: A Quantitative Autofluorescence Study **2015**, 56, 8179-86		36
74	Mouse slc9a8 mutants exhibit retinal defects due to retinal pigmented epithelium dysfunction **2015**, 56, 3015-26		9
73	CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa. *Molecular Therapy*, **2015**, 23, 1308-1319	11.7	52
72	Isoforms of Melanopsin Mediate Different Behavioral Responses to Light. *Current Biology*, **2015**, 25, 2430-4	9.3	24
71	Adeno-Associated Viral Gene Therapy for Retinal Disorders. *Neuromethods*, **2015**, 203-228	0.4	6
70	Gene Therapy for Choroideremia. *Essentials in Ophthalmology*, **2015**, 27-41	0.2	

69	Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 5, a017293	5.4	44
68	Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. *Lancet, The*, **2014**, 383, 1129-37	40	570
67	Vesicular stomatitis virus glycoprotein- and Venezuelan equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors differentially transduce corneal endothelium, trabecular meshwork, and human photoreceptors. *Human Gene Therapy*, **2014**, 25, 50-62	4.8	20
66	Unsutured phakic implantation of a black intraocular lens in the sulcus to treat leukocoria. *Journal of Cataract and Refractive Surgery*, **2014**, 40, 1565-7	2.3	0
65	Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study. *Journal of Tissue Engineering*, **2014**, 5, 2041731414551764	7.5	18
64	Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo. *Journal of Molecular Medicine*, **2013**, 91, 825-37	5.5	68
63	Reply: Cataract surgery and microphthalmic eyes. *Journal of Cataract and Refractive Surgery*, **2013**, 39, 818-9	2.3	4
62	Retinal Pigment Epithelium and Choroid Translocation in Patients with Age-Related Macular Degeneration **2013**, 2010-2018		1
61	Gene therapy for retinal disease. *Translational Research*, **2013**, 161, 241-54	11	54
60	Clinical applications of retinal gene therapy. *Progress in Retinal and Eye Research*, **2013**, 32, 22-47	20.5	89
59	X-linked cone dystrophy and colour vision deficiency arising from a missense mutation in a hybrid L/M cone opsin gene. *Vision Research*, **2013**, 80, 41-50	2.1	18
58	Macular hole surgery in patients with end-stage choroideremia. *Ophthalmology*, **2013**, 120, 1592-6	7.3	20
57	The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 Project. *Ophthalmology*, **2013**, 120, 623-628	7.3	32
56	Outcomes of phacoemulsification and intraocular lens implantation in microphthalmos and nanophthalmos. *Journal of Cataract and Refractive Surgery*, **2013**, 39, 87-96	2.3	47
55	Cone photoreceptor neuroprotection conferred by CNTF in a novel in vivo model of battlefield retinal laser injury **2013**, 54, 5456-65		4
54	Genome-wide association study identifies genetic risk underlying primary rhegmatogenous retinal detachment. *Human Molecular Genetics*, **2013**, 22, 3174-85	5.6	28
53	Fundus autofluorescence in the Abca4(-/-) mouse model of Stargardt disease--correlation with accumulation of A2E, retinal function, and histology **2013**, 54, 5602-12		74
52	Variations in opsin coding sequences cause x-linked cone dysfunction syndrome with myopia and dichromacy **2013**, 54, 1361-9		41

51	Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 1101-6	11.5	188
50	A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy **2013**, 54, 1665-78		33
49	Non-image-forming light driven functions are preserved in a mouse model of autosomal dominant optic atrophy. *PLoS ONE*, **2013**, 8, e56350	3.7	18
48	Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina. *PLoS ONE*, **2013**, 8, e60361	3.7	26
47	The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy. *PLoS ONE*, **2013**, 8, e82283	3.7	29
46	Translating induced pluripotent stem cells from bench to bedside: application to retinal diseases. *Current Gene Therapy*, **2013**, 13, 139-51	4.3	44
45	Non-viral retinal gene therapy: a review. *Clinical and Experimental Ophthalmology*, **2012**, 40, 39-47	2.4	28
44	Differential modulation of retinal degeneration by Ccl2 and Cx3cr1 chemokine signalling. *PLoS ONE* , **2012**, 7, e35551	3.7	49
43	Focus on molecules: neural retina leucine zipper (NRL). *Experimental Eye Research*, **2012**, 104, 99-100	3.7	4
42	Tetradecanoylphorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro. *Experimental Eye Research*, **2012**, 97, 148-53	3.7	3
41	Optimization of in vivo confocal autofluorescence imaging of the ocular fundus in mice and its application to models of human retinal degeneration **2012**, 53, 1066-75		52
40	Assessment of 180□rotation of the choroid as a novel surgical treatment for age-related macular degeneration **2012**, 53, 2523-32		
39	Recessive mutations in TSPAN12 cause retinal dysplasia and severe familial exudative vitreoretinopathy (FEVR) **2012**, 53, 2873-9		60
38	Leber congenital amaurosis associated with AIPL1: challenges in ascribing disease causation, clinical findings, and implications for gene therapy. *PLoS ONE*, **2012**, 7, e32330	3.7	26
37	Specific deficits in visual electrophysiology in a mouse model of dominant optic atrophy. *Experimental Eye Research*, **2011**, 93, 771-7	3.7	19
36	Combined phacoemulsification and removal of gas following macular hole surgery. *Journal of Cataract and Refractive Surgery*, **2011**, 37, 229-34	2.3	1
35	AAV-mediated gene transfer of human X-linked inhibitor of apoptosis protects against oxidative cell death in human RPE cells **2011**, 52, 9591-7		15
34	Assessment of cone survival in response to CNTF, GDNF, and VEGF165b in a novel ex vivo model of end-stage retinitis pigmentosa **2011**, 52, 7340-6		22

33	Responsiveness of choroidal neovascular membranes in patients with R345W mutation in fibulin 3 (Doyne honeycomb retinal dystrophy) to anti-vascular endothelial growth factor therapy. *JAMA Ophthalmology*, **2011**, 129, 1626-8		15
32	Combining M-FISH and Quantum Dot technology for fast chromosomal assignment of transgenic insertions. *BMC Biotechnology*, **2011**, 11, 121	3.5	6
31	Stem cells as a therapeutic tool for the blind: biology and future prospects. *Proceedings of the Royal Society B: Biological Sciences*, **2011**, 278, 3009-16	4.4	41
30	Characterization of a dominant cone degeneration in a green fluorescent protein-reporter mouse with disruption of Loci associated with human dominant retinal dystrophy **2011**, 52, 6617-23		12
29	Arterial occlusion after scleral buckling. *British Journal of Ophthalmology*, **2010**, 94, 503, 523-4	5.5	2
28	Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia **2010**, 51, 4913-20		68
27	Macular function assessed by microperimetry in patients with enhanced S-cone syndrome. *Ophthalmology*, **2010**, 117, 1199-1206.e1	7.3	33
26	Induced pluripotent stem cell therapies for retinal disease. *Current Opinion in Neurology*, **2010**, 23, 4-9	7.1	29
25	Long-term survival of photoreceptors transplanted into the adult murine neural retina requires immune modulation. *Stem Cells*, **2010**, 28, 1997-2007	5.8	98
24	The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages **2009**, 50, 5934-43		166
23	Long-term visual and microperimetry outcomes following autologous retinal pigment epithelium choroid graft for neovascular age-related macular degeneration. *Clinical and Experimental Ophthalmology*, **2009**, 37, 275-85	2.4	37
22	Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. *Journal of Gene Medicine*, **2009**, 11, 486-97	3.5	48
21	Scleral punch method with topical mitomycin C for safe revision of failed deep sclerectomy in nanophthalmic uveal effusion syndrome. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2009**, 247, 999-1001	3.8	9
20	An analysis of retinal gene therapy clinical trials. *Current Opinion in Molecular Therapeutics*, **2009**, 11, 540-6		8
19	Implantation of the black diaphragm intraocular lens in congenital and traumatic aniridia. *Ophthalmology*, **2008**, 115, 1705-12	7.3	46
18	Stickler syndrome. *Ophthalmology*, **2008**, 115, 1636-7; author reply 1637-8	7.3	5
17	Comparative analysis of progenitor cells isolated from the iris, pars plana, and ciliary body of the adult porcine eye. *Stem Cells*, **2007**, 25, 2430-8	5.8	77
16	Neuroprotective gene therapy for the treatment of inherited retinal degeneration. *Current Gene Therapy*, **2007**, 7, 434-45	4.3	23

15	Autologous transplantation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration. *Ophthalmology*, **2007**, 114, 561-70	7.3	103
14	Biometry and formula accuracy with intraocular lenses used for cataract surgery in extreme hyperopia. *American Journal of Ophthalmology*, **2007**, 143, 920-931	4.9	83
13	Variable phenotypes in patients diagnosed with idiopathic multifocal choroiditis. *Clinical and Experimental Ophthalmology*, **2006**, 34, 233-8	2.4	8
12	In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. *Molecular Therapy*, **2006**, 14, 700-9	11.7	83
11	Uveitic glaucoma and Rosai-Dorfman disease (sinus histiocytosis). *Ocular Immunology and Inflammation*, **2006**, 14, 305-7	2.8	6
10	CNTF gene transfer protects ganglion cells in rat retinae undergoing focal injury and branch vessel occlusion. *Experimental Eye Research*, **2006**, 83, 1118-27	3.7	34
9	Submacular Surgery: Author Reply. *Ophthalmology*, **2006**, 113, 1471-1472	7.3	
8	Effective gene therapy with nonintegrating lentiviral vectors. *Nature Medicine*, **2006**, 12, 348-53	50.5	368
7	Biometry accuracy using zero- and negative-powered intraocular lenses. *Journal of Cataract and Refractive Surgery*, **2005**, 31, 280-90	2.3	38
6	Long-term results of submacular surgery combined with macular translocation of the retinal pigment epithelium in neovascular age-related macular degeneration. *Ophthalmology*, **2005**, 112, 2081-7	7.3	85
5	Re-establishment of visual circuitry after optic nerve regeneration. *Eye*, **1999**, 13 (Pt 3a), 277-84	4.4	8
4	A glial palisade delineates the ipsilateral optic projection in Monodelphis. *Visual Neuroscience*, **1998** , 15, 397-400	1.7	4
3	Expression of myelin proteins in the opossum optic nerve: late appearance of inhibitors implicates an earlier non-myelin factor in preventing ganglion cell regeneration. *Journal of Comparative Neurology*, **1996**, 372, 27-36	3.4	22
2	Expression of myelin proteins in the opossum optic nerve: Late appearance of inhibitors implicates an earlier non-myelin factor in preventing ganglion cell regeneration **1996**, 372, 27		2
1	Rapid Quantification of the Binocular Visual Field for Clinical Trials: Performance of a Modified Esterman Supra-Threshold Test Implemented with the Open Perimetry Interface. *Clinical Ophthalmology*,Volume 16, 1513-1523	2.5	